TrivarX Ltd. engages in clinical research, product development, and early-stage commercialization of mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.
Follow-Up Questions
MDBIF 주식의 가격 성능은 어떻습니까?
MDBIF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
TrivarX Ltd의 주요 사업 주제나 업종은 무엇입니까?
TrivarX Ltd은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
